Journal List > Korean J Urogenit Tract Infect Inflamm > v.8(1) > 1059927

Shin and Ryu: Comparison between Fournier's Gangrene and Scrotal Abscess Using Fournier's Gangrene Severity Index

Abstract

Purpose

To evaluate effective factors in the survival of patients with Fournier's gangrene (FG) and scrotal abscess, and to determine the validity of the Fournier's gangrene severity index (FGSI), which was designed for determining disease severity in these patients.

Materials and Methods

Twenty-eight men who treated for FG were enrolled. The data were evaluated about medical history, extent of body surface area involved (%), and the FGSI, which index presents patients’ vital signs (body temperature, heart and respiratory rates) and metabolic parameters (serum sodium, potassium, creatinine, bicarbonate, hematocrit, and white blood cell count). All the patients had antibiotic treatment and radical surgical debridement. The data were assessed according to whether the patient of FG survived or died, and also compared in patients with scrotal abscess (n=26).

Results

Of the evaluated 28 FG patients, 6 died (21.4%). The difference in median age between survivors (57.5 years) and those who died (69.0 years) was not significant (p=0.18). Escherichia coli is the most common pathogen in 25% of FG and 15% of scrotal abscess patients. The median extent of the body surface area involved in patients who survived and died was 2.5% and 3.5%, respectively (p =0.13). However, the median FGSI scores for nonsurvivors and survivors of FG, and patients of scrotal abscess were 10.0±3.6, 3.3±2.6, and 0.9±2.6, respectively (p<0.01). The heart rate and serum creatinine level at the admission were significant prognostic parameters in patients with FG.

Conclusions

The FGSI score appeared to be predicts the disease severity and the patient's survival in patients with FG and scrotal abscess.

REFERENCES

1. Fournier JR. Gangrene foudroyante de la verge. Medicin Pratique. 1883; 4:597–8.
2. Spirnak JP, Resnick MI, Hampel N, Persky L. Fournier's gangrene: report of 20 patients. J Urol. 1984; 131:289–91.
3. Lim SD, Lee SJ, Jeong HJ. The study of prognostic factors in Fournier's gangrenes. Korean J Urol. 2002; 43:412–7.
4. Kim BH, Chang HS, Park CH, Kim CI, Kim KS. Necessity of aggressive management in fournier's gangrene. Korean J Urol. 2004; 45:793–9.
5. Weiner DM, Lowe FC. Gangrene of the male genitalia. AUA Update Series. 1998; 17:41–7.
6. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. J Urol. 1995; 154:89–92.
crossref
7. Lin E, Yang S, Chiu AW, Chow YC, Chen M, Lin WC, et al. Is Fournier's gangrene severity index useful for predicting outcome of Fournier's gangrene? Urol Int. 2005; 75:119–22.
crossref
8. Tuncel A, Aydin O, Tekdogan U, Nalcacioglu V, Capar Y, Atan A. Fournier's gangrene: Three years of experience with 20 patients and validity of the Fournier's Gangrene Severity Index Score. Eur Urol. 2006; 50:838–43.
crossref
9. Hwang EC, Na SW, Kim YJ, Kim JS, Kim SO, Jung SI, et al. Fournier's gangrene: six years of experience with 33 patients and validity of the Fournier's gangrene severity index score in Korean patients. Korean J UTII. 2010; 5:199–206.
10. Curreri PW, Luterman A. Burns. Schwartz SI, Shires GT, Spencer FC, editors. Principles of surgery. 5th ed.New York: McGraw-Hill Book Co.;1989. p. 285–306.
11. Laucks SS 2nd. Fournier's gangrene. Surg Clin North Am. 1994; 74:1339–52.
crossref
12. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg. 2000; 87:718–28.
crossref
13. Smith GL, Bunker CB, Dinneen MD. Fournier's gangrene. Br J Urol. 1998; 81:347–55.
crossref
14. Palmer LS, Winter HI, Tolia BM, Reid RE, Laor E. The limited impact of involved surface area and surgical débridement on survival in Fournier's gangrene. Br J Urol. 1995; 76:208–12.
15. Korkut M, Icoz G, Dayangac M, Akgun E, Yeniay L, Erdogan O, et al. Outcome analysis in patients with Fournier's gangrene: report of 45 cases. Dis Colon Rectum. 2003; 46:649–52.
16. Steffen EK, Hentges DJ. Hydrolytic enzymes of anaerobic bacteria isolated from human infections. J Clin Microbiol. 1981; 14:153–6.
crossref
17. Pizzorno R, Bonini F, Donelli A, Stubinski R, Medica M, Carmignani G. Hyperbaric oxygen therapy in the treatment of Fournier's disease in 11 male patients. J Urol. 1997; 158:837–40.
crossref
18. Clayton MD, Fowler JE Jr, Sharifi R, Pearl RK. Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet. 1990; 170:49–55.
19. Asci R, Sarikaya S, Buyukalpelli R, Yilmaz AF, Yildiz S. Fournier's gangrene: risk assessment and enzymatic debridement with lyophilized collagenase application. Eur Urol. 1998; 34:411–8.
20. Chawla SN, Gallop C, Mydlo JH. Fournier's gangrene: an analysis of repeated surgical debridement. Eur Urol. 2003; 43:572–5.
crossref
21. Kilic A, Aksoy Y, Kilic L. Fournier's gangrene: etiology, treatment, and complications. Ann Plast Surg. 2001; 47:523–7.

Table 1.
Fournier's gangrene severity index
Physical variable/point assignment High abnormal values Normal Low abnormal values
+4 +3 +2 +1 0 +1 +2 +3 +4
Temperature (°C) >40.9 39-40.9 - 38.5-38.9 36-38.4 34-35.9 32-33.9 30-31.9 <30
Heart rate (bpm) >179 140-179 110-139 - 70-109 - 55-69 40-54 <40
Respiratory rate (breaths per min) >49 35-49 - 25-34 12-24 10-11 6-9 - <6
Serum Na (mmol/l) >179 160-179 155-159 150-154 130-149 - 120-129 111-119 <111
Serum K (mmol/l) >6.9 6-6.9 - 5.5-5.9 3.5-5.4 3-3.4 2.5-2.9 - <2.5
Serum creatinine (mg/dl) >3.4 2-3.4 1.5-1.9 - 0.6-1.4 - <0.6 - -
Hematocrit (%)3 >59.9 - 50-59.9 46-49.9 30-45.9 - 20-29.9 - <20
White blood cell count (×103/mm3) >39.9 - 20-39.9 15-19.9 3-14.9 - 1-2.9 - <1
Serum bicarbonate (venous) (mmol/l) >51.9 41-51.9 - 32-40.9 22-31.9 - 18-21.9 15-17.9 <15

Adapted from Laor et al. J Urol 1995;154:89-92.6

Table 2.
Serum and hemodynamic parameters for patients with scrotal abscess, survivals and non-survivals of Fournier's gangrene
Variable Scrotal abscess (n=26) Fournier's gangrene (n=38)
Survivals (n=22) Non-survivals (n=6) p-valuea,b
Age (y) 50.5±16.1 57.5±19.0 69.0±13.8 0.18
Time to treat (d) 9.0±8.3 11.1±12.5 7.7±5.5 0.52
Hospital stay (d) 9.8±8.8 34.7±30.3 24.5±14.1 0.43
Body surface (%) - 2.5±16.1 3.5±16.1 0.13
FGSI score 0.9±2.6 3.3±2.6 10.0±3.6 <0.01
Temperature (°C) 36.5±0.5 36.8±0.7 36.9±1.0 0.74
Heart rate (bpm) 82.7±5.3 91.8±16.8 141.7±11.2 <0.01
Respiratory rate (breaths per min) 20.2±1.3 19.9±1.2 23.2±7.5 0.34
Serum Na (mmol/l) 137.8±3.1 135.7±3.4 135.4±8.3 0.53
Serum K (mmol/l) 3.8±0.5 3.8±0.6 3.7±0.8 0.61
Serum creatinine (mg/dl) 1.0±0.3 1.3±0.7 1.7±1.1 0.04
Hematocrit (%) 41.9±4.9 35.7±7.4 34.3±6.2 0.68
White blood cell count (×103/mm3) 11.7±2.1 15.7±9.4 22.1±7.2 0.14
Serum bicarbonate (mmol/l) 24.6±3.4 25.0±5.1 21.7±7.4 0.20

Values are presented as mean±standard deviation. FGSI: Fournier's gangrene severity index.

a Student's t-test

b Fisher's exact test.

Table 3.
Bacterial organisms from wound culture in patients withscrotal abscess and Fournier's gangrene
Organisms Scrotal abscess (n=26) Fournier's gangrene
Survivals (n=22) Non-survivals (n=6)
Escherichia coli 4 5 2
Enterococcus 0 2 1
Klebsiella 4 2 0
Coagulase-negative 2 2 0
Staphylococcus      
Methicillin-resistant 0 1 0
Staphylococcus aureus      
Streptococcus sp. 1 0 0
Candida 0 0 1
Pseudomonas 0 2 0
Morganella 0 0 1
Shewanella 0 0 1
Table 4.
Probability of survival or death according to Fournier's gangrene severity index threshold value of 9
  Fournier's gangrene severity index Probability (%)
9 or <9 >9
Survived 21 1 95.5
Died 2 4 66.7
TOOLS
Similar articles